Abstract:With the great success of anti-CTLA-4 and anti-PD-1 therapeutics in cancer immunotherapy, tumor necrosis factor receptor superfamily members have been recognized as ideal targets to provide co-stimulatory signals in combination with immune checkpoint blocking antibodies. Among these is OX40 (CD134), a co-stimulatory molecule expressed by activated immune cells. Recently, several anti-OX40 agonistic monoclonal antibodies, pogalizumab as the most advanced, have entered early phase clinical trials. Using a yeast platform and multiple screening methods, we identified a fully human anti-OX40 antibody (IBI101) with distinct modes of action. Unlike pogalizumab, IBI101 partially blocks the binding of OX40 to its ligand OX40L and exhibits both FcγR-dependent and independent agonistic activities in NF-κB luciferase reporter assays. IBI101 also promotes T cell activation and proliferation in vitro. These unique properties partially explain the more potent anti-tumor activity of IBI101 than that of pogalizumab in humanized NOG mice bearing LoVo tumors. In addition, IBI101 shows efficacious anti-tumor activity in mice when administrated alone or in combination with anti-PD-1 antibodies. In human OX40 knock-in mice bearing MC38 colon carcinoma, IBI101 treatment induces tumor antigen-specific CD8+ T-cell responses, decreases immunosuppressive regulatory T cells in tumor, and enhances the immune response to PD-1 inhibition. Preclinical studies of IBI101 in non-human primates demonstrate typical pharmacokinetic characteristics of an IgG antibody and no drug-related toxicity. Collectively, IBI101 has desirable preclinical attributes which support its clinical development for cancer treatment.

Preparation of Anti-Human OX40 Agonist Monoclonal Antibody and Its Biological Function

Preparation of Anti-Human OX40 Functional Monoclonal Antibody and Study of Its Biological Characteristics

Preparation and characterization of a novel monoclonal antibody against human PD-1

[Preparation and Characterization of Two Novel Functional Monoclonal Antibodies Against Human OX40L].

Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule.

[Preparation of a Novel Functional Anti-Human CD40 Monoclonal Antibody and Identification of Its Bioactivity].

A Novel Agonist Anti-Human Ox40l Monoclonal Antibody That Stimulates T Cell Proliferation and Enhances Cytokine Secretion

Preparation, Characterization and Application of Anti-Human OX40 Ligand (OX40L) Monoclonal Antibodies and Establishment of a Sandwich ELISA for Autoimmune Diseases Detection.

[Preparation and Characterization of a Mouse Anti-Human CD40 Mutant Monoclonal Antibody].

Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues.

Preparation of Anti-Human 4-1BB Monoclonal Antibody and Analysis of Its Biological Functions

Preparation of a functional monoclonal antibody against human 4-1BBL molecule and analysis of its biological characteristics

Generation and Characterization of a High‐affinity Chimeric Anti‐ox40 Antibody with Potent Antitumor Activity

Construction, Eukaryotic Expression, and Characterization of Human OX40-Fc Molecule

Preparation of anti-human 4-1BB monoclonal antibody and characterization of its biological activities]

Expression of Human OX40L in BL21 {\sl E. Coli} and Studies on Its Biological Function

[Preparation and Characterization of a Novel Functional Anti-Human CD83 Monoclonal Antibody].

Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function

Preparation and enhanced eukaryotic expression of anti-human CD40 antibodies

Preparation and Biological Characterization of a Mouse Anti-Human Monoclonal Antibody Against TLT-2

Development and Characterization of a Novel Anti-Ox40 Antibody for Potent Immune Activation